Rapamycin and rapamycin derivatives potently inhibit growth of solid tumor cell lines, and rapamycin has been shown to enhance survival and reduce tumor burden in several cancer-prone mouse models, including heterozygous p53+/− [169], heterozygous Rb +/− mice [170], and multiple tumor xenograft models [171–176]. Here, TP53 is linked to neoplasm.